SG11202111188VA - Anti-cd40 antibody and use thereof - Google Patents

Anti-cd40 antibody and use thereof

Info

Publication number
SG11202111188VA
SG11202111188VA SG11202111188VA SG11202111188VA SG11202111188VA SG 11202111188V A SG11202111188V A SG 11202111188VA SG 11202111188V A SG11202111188V A SG 11202111188VA SG 11202111188V A SG11202111188V A SG 11202111188VA SG 11202111188V A SG11202111188V A SG 11202111188VA
Authority
SG
Singapore
Prior art keywords
antibody
Prior art date
Application number
SG11202111188VA
Inventor
Hongkai Zhang
Yuan Wang
Original Assignee
Univ Nankai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nankai filed Critical Univ Nankai
Publication of SG11202111188VA publication Critical patent/SG11202111188VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202111188VA 2019-04-10 2020-04-10 Anti-cd40 antibody and use thereof SG11202111188VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910284441 2019-04-10
CN202010262466 2020-04-03
PCT/CN2020/084186 WO2020207470A1 (en) 2019-04-10 2020-04-10 Anti-cd40 antibody and use thereof

Publications (1)

Publication Number Publication Date
SG11202111188VA true SG11202111188VA (en) 2021-11-29

Family

ID=72752143

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111188VA SG11202111188VA (en) 2019-04-10 2020-04-10 Anti-cd40 antibody and use thereof

Country Status (9)

Country Link
US (1) US20220324988A1 (en)
EP (1) EP3954705A4 (en)
JP (1) JP7535060B2 (en)
CN (1) CN113728008B (en)
AU (1) AU2020256828A1 (en)
CA (1) CA3136491A1 (en)
SG (1) SG11202111188VA (en)
TW (1) TW202103733A (en)
WO (1) WO2020207470A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373590B1 (en) * 2020-09-22 2022-03-14 (주)아이엠지티 Novel nanoparticles using anionic polymers, preparation method and composition thereof
CN116120451A (en) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 anti-CD 70 internalizing antibodies, antibody conjugates and uses thereof
CN117229396A (en) * 2022-06-06 2023-12-15 普米斯生物技术(珠海)有限公司 anti-CD 40 antibodies and uses thereof
US20240279350A1 (en) * 2023-02-16 2024-08-22 Sanofi CD40-Binding Proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
AU2012249454B2 (en) * 2011-04-29 2016-03-24 Apexigen, Inc. Anti-CD40 antibodies and methods of use
CN109265552A (en) * 2012-10-30 2019-01-25 埃派斯进有限公司 Anti-CD 40 antibodies and its application method
GB201308658D0 (en) 2013-05-14 2013-06-26 Isis Innovation Antibodies
EP3964527A3 (en) * 2015-04-13 2022-06-15 Five Prime Therapeutics, Inc. Combination therapy for cancer
EP3292143B1 (en) 2015-05-04 2019-08-21 Apogenix AG Single-chain cd40-receptor agonist proteins
CN107771184B (en) 2015-06-29 2022-11-01 百时美施贵宝公司 Antibodies against CD40
MX2017016502A (en) * 2015-06-29 2018-03-12 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity.
AU2016315873B2 (en) * 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
MA43053A (en) * 2015-09-30 2018-08-08 Janssen Biotech Inc ANTAGONIST ANTIBODIES BINDING SPECIFICALLY TO HUMAN CD40 AND METHODS OF USE
WO2017184619A2 (en) * 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
PT3464361T (en) * 2016-05-27 2021-12-27 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
WO2017211321A1 (en) * 2016-06-08 2017-12-14 上海交通大学医学院 Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
US11702478B2 (en) * 2017-09-19 2023-07-18 Mab Discovery Gmbh Agonistic CD40 antibodies

Also Published As

Publication number Publication date
AU2020256828A1 (en) 2021-11-18
CA3136491A1 (en) 2020-10-15
US20220324988A1 (en) 2022-10-13
JP7535060B2 (en) 2024-08-15
CN113728008B (en) 2024-04-09
CN113728008A (en) 2021-11-30
JP2022527406A (en) 2022-06-01
EP3954705A1 (en) 2022-02-16
TW202103733A (en) 2021-02-01
WO2020207470A1 (en) 2020-10-15
EP3954705A4 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
EP3889179A4 (en) Bispecific antibody and use thereof
EP3904386A4 (en) Antibody and use thereof
ZA202006904B (en) Anti-il-4r antibody and use thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
EP3797124A4 (en) Anti-ror1 antibody and use thereof
EP3887403A4 (en) Anti-4-1bb antibody and use thereof
EP3802612A4 (en) Anti-b7-h3 antibody and use thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
EP3907240A4 (en) Anti-tnfr2 antibody and use thereof
EP3819313A4 (en) Bispecific antibody and use thereof
SG11202111188VA (en) Anti-cd40 antibody and use thereof
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL289269A (en) Anti-cd24 antibody and uses thereof
ZA202006255B (en) Anti-pd-l1 antibody and use thereof
EP3632933A4 (en) Novel anti-cd40 antibodies and use thereof
IL287690A (en) Anti-hvem antibodies and use thereof
EP4036113A4 (en) Humanized anti-il17a antibody and use thereof
IL280281A (en) Anti-cd40 antibodies and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
IL282707A (en) Anti-tim-3 antibodies and their use
EP4083069A4 (en) Anti-ox40 antibody and use thereof
EP4032904A4 (en) Anti-alpha-hemolysin antibody and use thereof
IL285569A (en) Anti-pd-l1 antibody and use thereof
IL289656A (en) Anti-tigit antibodies and application thereof